Overview of Cladribine
| Property | Description |
|---|---|
| Active ingredient | Cladribine (2-chlorodeoxyadenosine, 2-CdA) |
| Form | Oral tablets and solution for injection/infusion |
| Pharmacological class | Purine Nucleoside Analogue, Selective Immunosuppressive Agent, Antimetabolite |
| General Purpose | Long-term modulation and modification of the immune system activity |
| Origin | Synthetic compound (derived from natural purine) |
Cladribine is a synthetic purine nucleoside analogue defined as a highly potent selective immunosuppressive agent and a member of the antineoplastic agent pharmacological class. It is utilized as a foundational medication intended to modify the underlying activity of the immune system in certain chronic conditions. The drug’s classification reflects its potent ability to interfere with cell growth and survival, offering a focused therapeutic effect on the immune response. Its mechanism allows for achieving sustained therapeutic benefit through periodic treatment.
What Type of Medicine is Cladribine?
The medication's active ingredient is Cladribine, chemically referred to as 2-chlorodeoxyadenosine (2-CdA), which is a synthesized derivative of a naturally occurring DNA building block. This chemical structure places it within the category of antimetabolites, meaning it interferes with the normal reproductive cycles of certain cells. The drug’s pharmacological properties allow it to act as a selective immune reconstitution therapy. This characteristic action—achieving a sustained effect through short, distinct treatment courses—is a differentiating factor from therapies requiring continuous, daily administration. Popular brands utilizing this INN include Mavenclad (tablets), Leustatin, and Litak (injection/infusion forms).
Composition and Forms of Cladribine
Cladribine is provided as a single active ingredient product available in two main dosage forms: a convenient oral tablet and a sterile solution for injection or infusion (parenteral form). The oral formulation is a non-invasive option, while the parenteral solution is administered via the intravenous or subcutaneous route. The primary purpose of this drug is long-term immune system modulation for patients dealing with conditions driven by autoimmune or lymphocyte activity.
The Principle of Cladribine's Selective Action
The fundamental purpose of Cladribine lies in its ability to preferentially target and deplete specific, overactive immune cells, primarily lymphocytes (T-cells and B-cells). Its unique properties allow it to accumulate in these cells, leading to their programmed death (apoptosis). This selective depletion of B- and T-cells, which are implicated in disease development, is the basis for its general purpose in establishing long-term, sustained immune system modulation by reducing the populations of cells responsible for unwanted activity.
Regulatory References
